Skip to main content
Top
Gepubliceerd in: Quality of Life Research 10/2018

19-06-2018

Association between quality of life and clinical characteristics in patients with morphea

Auteurs: G. Bali, S. Kárpáti, M. Sárdy, V. Brodszky, B. Hidvégi, F. Rencz

Gepubliceerd in: Quality of Life Research | Uitgave 10/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Background

Morphea can lead to considerable cosmetic or functional impairment; nevertheless, health-related quality of life (HRQoL) is rarely documented in adult morphea patients.

Objective

To investigate the impact of morphea on HRQoL and to identify determinants of impaired HRQoL.

Methods

A cross-sectional study has been carried out among adult morphea patients. HRQoL was evaluated by the Dermatology Life Quality Index (DLQI). The modified Localised Scleroderma Skin Severity Index (mLoSSI) and the Localised Scleroderma Damage Index (LoSDI) were applied to evaluate disease activity and damage, respectively. Physician Global Assessment of Activity and Damage (PGA-A, PGA-D) were also completed. Determinants of HRQoL were analysed by multiple regression.

Results

A total of 101 patients (84% females) entered the study, with a mean age of 56.8 ± 14.8 years. Median mLoSSI, LoSDI, PGA-A and PGA-D scores were 8, 5, 9 and 9 points, respectively. Patients with generalised localised (51%) and plaque-type morphea (45%) had median total DLQI scores of 4 and 1, respectively. Embarrassment (53%), itchy or painful skin (46%), and clothing issues (43%) were the most commonly reported problems in the DLQI. Female gender, generalised morphea, higher disease activity (PGA-A score) and involvement of hands and/or feet were significant predictors of impaired HRQoL (p < 0.05).

Conclusion

This study represents the largest sample of adult morphea patients surveyed about their HRQoL in Europe. The frequent occurrence of embarrassment warrants an increased attention to improve patients’ mental health. Care must be taken in case of involvement of functionally sensitive areas, as these cases might require more intensive treatment.
Literatuur
1.
go back to reference Silman, A., Jannini, S., Symmons, D., & Bacon, P. (1988). An epidemiological study of scleroderma in the West Midlands. British Journal of Rheumatology, 27(4), 286–290.CrossRefPubMed Silman, A., Jannini, S., Symmons, D., & Bacon, P. (1988). An epidemiological study of scleroderma in the West Midlands. British Journal of Rheumatology, 27(4), 286–290.CrossRefPubMed
2.
go back to reference Peterson, L. S., Nelson, A. M., Su, W. P., Mason, T., O’Fallon, W. M., & Gabriel, S. E. (1997). The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. Journal of Rheumatology, 24(1), 73–80.PubMed Peterson, L. S., Nelson, A. M., Su, W. P., Mason, T., O’Fallon, W. M., & Gabriel, S. E. (1997). The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. Journal of Rheumatology, 24(1), 73–80.PubMed
3.
go back to reference Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., et al. (2017). European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 31(9), 1401–1424.CrossRefPubMed Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., et al. (2017). European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. Journal of the European Academy of Dermatology and Venereology, 31(9), 1401–1424.CrossRefPubMed
4.
go back to reference Das, S., Bernstein, I., & Jacobe, H. (2014). Correlates of self-reported quality of life in adults and children with morphea. Journal of the American Academy of Dermatology, 70(5), 904–910.CrossRefPubMedPubMedCentral Das, S., Bernstein, I., & Jacobe, H. (2014). Correlates of self-reported quality of life in adults and children with morphea. Journal of the American Academy of Dermatology, 70(5), 904–910.CrossRefPubMedPubMedCentral
5.
go back to reference Tollefson, M. M., & Witman, P. M. (2007). En coup de sabre morphea and Parry-Romberg syndrome: A retrospective review of 54 patients. Journal of the American Academy of Dermatology, 56(2), 257–263.CrossRefPubMed Tollefson, M. M., & Witman, P. M. (2007). En coup de sabre morphea and Parry-Romberg syndrome: A retrospective review of 54 patients. Journal of the American Academy of Dermatology, 56(2), 257–263.CrossRefPubMed
6.
go back to reference Bielsa, I., & Ariza, A. (2007). Deep morphea. Seminars in Cutaneous Medicine and Surgery, 26(2), 90–95.CrossRefPubMed Bielsa, I., & Ariza, A. (2007). Deep morphea. Seminars in Cutaneous Medicine and Surgery, 26(2), 90–95.CrossRefPubMed
7.
go back to reference Christen-Zaech, S., Hakim, M. D., Afsar, F. S., & Paller, A. S. (2008). Pediatric morphea (localized scleroderma): Review of 136 patients. Journal of the American Academy of Dermatology, 59(3), 385–396.CrossRefPubMed Christen-Zaech, S., Hakim, M. D., Afsar, F. S., & Paller, A. S. (2008). Pediatric morphea (localized scleroderma): Review of 136 patients. Journal of the American Academy of Dermatology, 59(3), 385–396.CrossRefPubMed
8.
go back to reference Leitenberger, J. J., Cayce, R. L., Haley, R. W., Adams-Huet, B., Bergstresser, P. R., & Jacobe, H. T. (2009). Distinct autoimmune syndromes in morphea: A review of 245 adult and pediatric cases. Archives of Dermatology, 145(5), 545–550.CrossRefPubMedPubMedCentral Leitenberger, J. J., Cayce, R. L., Haley, R. W., Adams-Huet, B., Bergstresser, P. R., & Jacobe, H. T. (2009). Distinct autoimmune syndromes in morphea: A review of 245 adult and pediatric cases. Archives of Dermatology, 145(5), 545–550.CrossRefPubMedPubMedCentral
9.
go back to reference Mills, S. D., Fox, R. S., & Malcarne, V. L. (2015). Body image in children with morphea: A systematic review. Pediatric Dermatology, 32(4), e188–e190.CrossRefPubMed Mills, S. D., Fox, R. S., & Malcarne, V. L. (2015). Body image in children with morphea: A systematic review. Pediatric Dermatology, 32(4), e188–e190.CrossRefPubMed
10.
go back to reference Lis-Swiety, A., Janicka, I., Skrzypek-Salamon, A., & Brzezinska-Wcislo, L. (2017). A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. Journal of the American Academy of Dermatology, 31(1), 30–37.CrossRef Lis-Swiety, A., Janicka, I., Skrzypek-Salamon, A., & Brzezinska-Wcislo, L. (2017). A systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients. Journal of the American Academy of Dermatology, 31(1), 30–37.CrossRef
11.
go back to reference Klimas, N. K., Shedd, A. D., Bernstein, I. H., & Jacobe, H. (2015). Health-related quality of life in morphoea. British Journal of Dermatology, 172(5), 1329–1337.CrossRefPubMed Klimas, N. K., Shedd, A. D., Bernstein, I. H., & Jacobe, H. (2015). Health-related quality of life in morphoea. British Journal of Dermatology, 172(5), 1329–1337.CrossRefPubMed
12.
go back to reference Kroft, E. B., de Jong, E. M., & Evers, A. W. (2009). Psychological distress in patients with morphea and eosinophilic fasciitis. Archives of Dermatology, 145(9), 1017–1022.CrossRefPubMed Kroft, E. B., de Jong, E. M., & Evers, A. W. (2009). Psychological distress in patients with morphea and eosinophilic fasciitis. Archives of Dermatology, 145(9), 1017–1022.CrossRefPubMed
13.
go back to reference Kroft, E. B., de Jong, E. M., & Evers, A. W. (2008). Physical burden of symptoms in patients with localized scleroderma and eosinophilic fasciitis. Archives of Dermatology, 144(10), 1394–1395.CrossRefPubMed Kroft, E. B., de Jong, E. M., & Evers, A. W. (2008). Physical burden of symptoms in patients with localized scleroderma and eosinophilic fasciitis. Archives of Dermatology, 144(10), 1394–1395.CrossRefPubMed
14.
go back to reference Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2014). Quality of life and optimism in patients with morphea. Applied Research in Quality of Life, 9(4), 863–870.CrossRefPubMed Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2014). Quality of life and optimism in patients with morphea. Applied Research in Quality of Life, 9(4), 863–870.CrossRefPubMed
15.
go back to reference Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2013). Health-related quality of life, optimism, and coping strategies in persons suffering from localized scleroderma. Psychology, Health & Medicine, 18(6), 654–663.CrossRef Szramka-Pawlak, B., Danczak-Pazdrowska, A., Rzepa, T., Szewczyk, A., Sadowska-Przytocka, A., & Zaba, R. (2013). Health-related quality of life, optimism, and coping strategies in persons suffering from localized scleroderma. Psychology, Health & Medicine, 18(6), 654–663.CrossRef
16.
go back to reference Orzechowski, N. M., Davis, D. M., Mason, T. G. 3rd, Crowson, C. S., & Reed, A. M. (2009). Health-related quality of life in children and adolescents with juvenile localized scleroderma. Rheumatology, 48(6), 670–672.CrossRefPubMed Orzechowski, N. M., Davis, D. M., Mason, T. G. 3rd, Crowson, C. S., & Reed, A. M. (2009). Health-related quality of life in children and adolescents with juvenile localized scleroderma. Rheumatology, 48(6), 670–672.CrossRefPubMed
17.
go back to reference Mertens, J. S., Thurlings, R. M., Kievit, W., Seyger, M. M. B., Radstake, T. R. D., & de Jong, E. (2017). Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients. Journal of the American Academy of Dermatology, 77(3), 512–517 e515.CrossRefPubMed Mertens, J. S., Thurlings, R. M., Kievit, W., Seyger, M. M. B., Radstake, T. R. D., & de Jong, E. (2017). Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients. Journal of the American Academy of Dermatology, 77(3), 512–517 e515.CrossRefPubMed
18.
go back to reference van der Linden, M. M., van Rappard, D. C., Daams, J. G., Sprangers, M. A., Spuls, P. I., & de Korte, J. (2015). Health-related quality of life in patients with cutaneous rosacea: A systematic review. Acta Dermato-Venereologica, 95(4), 395–400.CrossRefPubMed van der Linden, M. M., van Rappard, D. C., Daams, J. G., Sprangers, M. A., Spuls, P. I., & de Korte, J. (2015). Health-related quality of life in patients with cutaneous rosacea: A systematic review. Acta Dermato-Venereologica, 95(4), 395–400.CrossRefPubMed
19.
go back to reference Gerard, A. J., Feldman, S. R., & Strowd, L. (2015). Quality of life of patients with pyoderma gangrenosum and hidradenitis suppurativa. Journal of Cutaneous Medicine and Surgery, 19(4), 391–396.CrossRefPubMed Gerard, A. J., Feldman, S. R., & Strowd, L. (2015). Quality of life of patients with pyoderma gangrenosum and hidradenitis suppurativa. Journal of Cutaneous Medicine and Surgery, 19(4), 391–396.CrossRefPubMed
20.
go back to reference Rencz, F., Gulacsi, L., Pentek, M., Wikonkal, N., Baji, P., & Brodszky, V. (2016). Alopecia areata and health-related quality of life: A systematic review and meta-analysis. British Journal of Dermatology, 175(3), 561–571.CrossRefPubMed Rencz, F., Gulacsi, L., Pentek, M., Wikonkal, N., Baji, P., & Brodszky, V. (2016). Alopecia areata and health-related quality of life: A systematic review and meta-analysis. British Journal of Dermatology, 175(3), 561–571.CrossRefPubMed
21.
go back to reference Rencz, F., Gulacsi, L., Tamasi, B., Karpati, S., Pentek, M., Baji, P., et al. (2015). Health-related quality of life and its determinants in pemphigus: A systematic review and meta-analysis. British Journal of Dermatology, 173(4), 1076–1080.CrossRefPubMed Rencz, F., Gulacsi, L., Tamasi, B., Karpati, S., Pentek, M., Baji, P., et al. (2015). Health-related quality of life and its determinants in pemphigus: A systematic review and meta-analysis. British Journal of Dermatology, 173(4), 1076–1080.CrossRefPubMed
22.
go back to reference Hill, M. K., Kheirandish Pishkenari, A., Braunberger, T. L., Armstrong, A. W., & Dunnick, C. A. (2016). Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. Journal of the American Academy of Dermatology, 75(5), 906–917.CrossRefPubMed Hill, M. K., Kheirandish Pishkenari, A., Braunberger, T. L., Armstrong, A. W., & Dunnick, C. A. (2016). Recent trends in disease severity and quality of life instruments for patients with atopic dermatitis: A systematic review. Journal of the American Academy of Dermatology, 75(5), 906–917.CrossRefPubMed
23.
go back to reference Amer, A. A., & Gao, X. H. (2016). Quality of life in patients with vitiligo: An analysis of the dermatology life quality index outcome over the past two decades. International Journal of Dermatology, 55(6), 608–614.CrossRefPubMed Amer, A. A., & Gao, X. H. (2016). Quality of life in patients with vitiligo: An analysis of the dermatology life quality index outcome over the past two decades. International Journal of Dermatology, 55(6), 608–614.CrossRefPubMed
24.
go back to reference Gaulin, C., Sebaratnam, D. F., & Fernandez-Penas, P. (2015). Quality of life in non-melanoma skin cancer. Australasian Journal of Dermatology, 56(1), 70–76.CrossRefPubMed Gaulin, C., Sebaratnam, D. F., & Fernandez-Penas, P. (2015). Quality of life in non-melanoma skin cancer. Australasian Journal of Dermatology, 56(1), 70–76.CrossRefPubMed
25.
go back to reference Almeida, C., Almeida, I., & Vasconcelos, C. (2015). Quality of life in systemic sclerosis. Autoimmunity Reviews, 14(12), 1087–1096.CrossRefPubMed Almeida, C., Almeida, I., & Vasconcelos, C. (2015). Quality of life in systemic sclerosis. Autoimmunity Reviews, 14(12), 1087–1096.CrossRefPubMed
26.
go back to reference Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.CrossRefPubMed Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.CrossRefPubMed
27.
go back to reference Arkachaisri, T., Vilaiyuk, S., Torok, K. S., & Medsger, T. A. Jr. (2010). Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: A proof-of-concept study. Rheumatology, 49(2), 373–381.CrossRefPubMed Arkachaisri, T., Vilaiyuk, S., Torok, K. S., & Medsger, T. A. Jr. (2010). Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: A proof-of-concept study. Rheumatology, 49(2), 373–381.CrossRefPubMed
28.
go back to reference Kelsey, C. E., & Torok, K. S. (2013). The localized scleroderma cutaneous assessment tool: Responsiveness to change in a pediatric clinical population. Journal of the American Academy of Dermatology, 69(2), 214–220.CrossRefPubMedPubMedCentral Kelsey, C. E., & Torok, K. S. (2013). The localized scleroderma cutaneous assessment tool: Responsiveness to change in a pediatric clinical population. Journal of the American Academy of Dermatology, 69(2), 214–220.CrossRefPubMedPubMedCentral
29.
go back to reference Arkachaisri, T., & Pino, S. (2008). Localized scleroderma severity index and global assessments: A pilot study of outcome instruments. The Journal of Rheumatology, 35(4), 650–657.PubMed Arkachaisri, T., & Pino, S. (2008). Localized scleroderma severity index and global assessments: A pilot study of outcome instruments. The Journal of Rheumatology, 35(4), 650–657.PubMed
30.
go back to reference Arkachaisri, T., Vilaiyuk, S., Li, S., O’Neil, K. M., Pope, E., Higgins, G. C., et al. (2009). The localized scleroderma skin severity index and physician global assessment of disease activity: A work in progress toward development of localized scleroderma outcome measures. The Journal of Rheumatology, 36(12), 2819–2829.CrossRefPubMedPubMedCentral Arkachaisri, T., Vilaiyuk, S., Li, S., O’Neil, K. M., Pope, E., Higgins, G. C., et al. (2009). The localized scleroderma skin severity index and physician global assessment of disease activity: A work in progress toward development of localized scleroderma outcome measures. The Journal of Rheumatology, 36(12), 2819–2829.CrossRefPubMedPubMedCentral
31.
go back to reference Swinscow, T. D. V., & Campbell, M. J. (2002). Statistics at square one. BMJ: London. Swinscow, T. D. V., & Campbell, M. J. (2002). Statistics at square one. BMJ: London.
32.
go back to reference Rencz, F., Poór, A. K., Péntek, M., Holló, P., Kárpáti, S., Gulácsi, L., et al. (2018). A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: Potential biases in treatment decisions. Journal of the European Academy of Dermatology and Venereology, 32(5), 783–790.CrossRefPubMed Rencz, F., Poór, A. K., Péntek, M., Holló, P., Kárpáti, S., Gulácsi, L., et al. (2018). A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: Potential biases in treatment decisions. Journal of the European Academy of Dermatology and Venereology, 32(5), 783–790.CrossRefPubMed
33.
go back to reference Ardalan, K., Zigler, C. K., & Torok, K. S. (2017). Predictors of longitudinal quality of life in Juvenile localized Scleroderma. Arthritis Care & Research, 69(7), 1082–1087.CrossRef Ardalan, K., Zigler, C. K., & Torok, K. S. (2017). Predictors of longitudinal quality of life in Juvenile localized Scleroderma. Arthritis Care & Research, 69(7), 1082–1087.CrossRef
34.
go back to reference Sampogna, F., Raskovic, D., Guerra, L., Pedicelli, C., Tabolli, S., Leoni, L., et al. (2008). Identification of categories at risk for high quality of life impairment in patients with vitiligo. British Journal of Dermatology, 159(2), 351–359.CrossRefPubMed Sampogna, F., Raskovic, D., Guerra, L., Pedicelli, C., Tabolli, S., Leoni, L., et al. (2008). Identification of categories at risk for high quality of life impairment in patients with vitiligo. British Journal of Dermatology, 159(2), 351–359.CrossRefPubMed
35.
go back to reference Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics, 15(Suppl 1), S111–S119.CrossRefPubMed Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics, 15(Suppl 1), S111–S119.CrossRefPubMed
36.
go back to reference Ongenae, K., Dierckxsens, L., Brochez, L., van Geel, N., & Naeyaert, J. M. (2005). Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology, 210(4), 279–285.CrossRefPubMed Ongenae, K., Dierckxsens, L., Brochez, L., van Geel, N., & Naeyaert, J. M. (2005). Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology, 210(4), 279–285.CrossRefPubMed
37.
go back to reference Schmid-Ott, G., Kuensebeck, H. W., Jaeger, B., Werfel, T., Frahm, K., Ruitman, J., et al. (1999). Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Dermato-Venereologica, 79(6), 443–447.CrossRefPubMed Schmid-Ott, G., Kuensebeck, H. W., Jaeger, B., Werfel, T., Frahm, K., Ruitman, J., et al. (1999). Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients. Acta Dermato-Venereologica, 79(6), 443–447.CrossRefPubMed
38.
go back to reference Schmid-Ott, G., Kunsebeck, H. W., Jager, B., Sittig, U., Hofste, N., Ott, R., et al. (2005). Significance of the stigmatization experience of psoriasis patients: A 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Dermato-Venereologica, 85(1), 27–32.CrossRefPubMed Schmid-Ott, G., Kunsebeck, H. W., Jager, B., Sittig, U., Hofste, N., Ott, R., et al. (2005). Significance of the stigmatization experience of psoriasis patients: A 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Dermato-Venereologica, 85(1), 27–32.CrossRefPubMed
39.
go back to reference van Beugen, S., van Middendorp, H., Ferwerda, M., Smit, J. V., Zeeuwen-Franssen, M. E., Kroft, E. B., et al. (2017). Predictors of perceived stigmatization in patients with psoriasis. British Journal of Dermatology, 176(3), 687–694.CrossRefPubMed van Beugen, S., van Middendorp, H., Ferwerda, M., Smit, J. V., Zeeuwen-Franssen, M. E., Kroft, E. B., et al. (2017). Predictors of perceived stigmatization in patients with psoriasis. British Journal of Dermatology, 176(3), 687–694.CrossRefPubMed
Metagegevens
Titel
Association between quality of life and clinical characteristics in patients with morphea
Auteurs
G. Bali
S. Kárpáti
M. Sárdy
V. Brodszky
B. Hidvégi
F. Rencz
Publicatiedatum
19-06-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 10/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1897-1

Andere artikelen Uitgave 10/2018

Quality of Life Research 10/2018 Naar de uitgave